Jonas Bergh Selected Research

Epirubicin (Ellence)

10/2022	Event-free Survival with Pembrolizumab in Early Triple-Negative Breast Cancer.
7/2020	Leukocyte nadir as a predictive factor for efficacy of adjuvant chemotherapy in breast cancer. Results from the prospective trial SBG 2000-1.
5/2020	Long-term (up to 16 months) health-related quality of life after adjuvant tailored dose-dense chemotherapy vs. standard three-weekly chemotherapy in women with high-risk early breast cancer.
1/2020	Pembrolizumab for Early Triple-Negative Breast Cancer.
1/2020	Neutropenic complications in the PANTHER phase III study of adjuvant tailored dose-dense chemotherapy in early breast cancer.
1/2018	Assessment of early response biomarkers in relation to long-term survival in patients with HER2-negative breast cancer receiving neoadjuvant chemotherapy plus bevacizumab: Results from the Phase II PROMIX trial.
1/2018	Dynamic evaluation of the immune infiltrate and immune function genes as predictive markers for neoadjuvant chemotherapy in hormone receptor positive, HER2 negative breast cancer.
4/2017	Contrast-enhanced ultrasound (CEUS) in assessing early response among patients with invasive breast cancer undergoing neoadjuvant chemotherapy.
6/2011	TP53 status for prediction of sensitivity to taxane versus non-taxane neoadjuvant chemotherapy in breast cancer (EORTC 10994/BIG 1-00): a randomised phase 3 trial.
4/2011	Tailored chemotherapy doses based on toxicity in breast cancer result in similar quality of life values, irrespective of given dose levels.

For more, sign up at right for free...

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Jonas Bergh Research Topics

Disease

140	Breast Neoplasms (Breast Cancer) 07/2022 - 01/2002
101	Neoplasms (Cancer) 10/2022 - 01/2002
18	Neoplasm Metastasis (Metastasis) 07/2022 - 03/2004
6	Nausea 01/2019 - 05/2007
5	Triple Negative Breast Neoplasms 10/2022 - 07/2014
5	Renal Cell Carcinoma (Grawitz Tumor) 11/2020 - 01/2012
5	Fatigue 05/2020 - 04/2011
5	Disease Progression 01/2020 - 11/2008
5	Vomiting 01/2019 - 05/2007
4	Neutropenia 01/2020 - 12/2005
4	Carcinoma (Carcinomatosis) 10/2019 - 07/2006
4	Multiple Myeloma 01/2019 - 11/2017
4	Diarrhea 01/2018 - 07/2014
3	Heart Diseases (Heart Disease) 01/2022 - 09/2007
3	Inflammation (Inflammations) 01/2021 - 07/2014
3	Leukopenia 07/2020 - 04/2011
3	Aneuploidy (Aneuploid) 01/2020 - 03/2004
3	Lung Neoplasms (Lung Cancer) 01/2019 - 05/2017
2	Heart Failure 01/2022 - 09/2007
2	Pathologic Complete Response 01/2021 - 01/2018
2	Noninfiltrating Intraductal Carcinoma (DCIS) 01/2021 - 01/2019
2	Sarcoma (Soft Tissue Sarcoma) 12/2020 - 11/2008
2	Febrile Neutropenia 01/2020 - 01/2011
2	Precursor Cell Lymphoblastic Leukemia-Lymphoma (Acute Lymphoblastic Leukemia) 01/2020 - 01/2020
2	Infections 01/2020 - 01/2011
2	Hypertension (High Blood Pressure) 12/2017 - 02/2015
2	Carcinogenesis 11/2017 - 06/2006
2	Lymphatic Metastasis 11/2011 - 11/2006
2	Genomic Instability 05/2011 - 05/2011
1	Myocardial Ischemia (Ischemic Heart Diseases) 01/2022

Drug/Important Bio-Agent (IBA)

24	Estrogen ReceptorsIBA 07/2022 - 03/2004
22	Epirubicin (Ellence)FDA LinkGeneric 10/2022 - 01/2002
20	Cyclophosphamide (Cytoxan)FDA LinkGeneric 10/2022 - 01/2002
18	Hormones (Hormone)IBA 08/2021 - 02/2006
17	Biomarkers (Surrogate Marker)IBA 03/2021 - 07/2006
17	Docetaxel (Taxotere)FDA Link 01/2021 - 12/2007
16	Tamoxifen FDA LinkGeneric 01/2022 - 07/2003
16	Proteins (Proteins, Gene)FDA Link 09/2021 - 12/2003
15	Fluorouracil (Carac)FDA LinkGeneric 05/2020 - 01/2002
14	Trastuzumab (Herceptin)FDA Link 01/2022 - 01/2002
13	Biological ProductsIBA 01/2021 - 01/2006
11	Phenobarbital (Luminal)FDA Link 10/2019 - 07/2005
10	Progesterone Receptors (Progesterone Receptor)IBA 01/2021 - 09/2006
8	RNA (Ribonucleic Acid)IBA 09/2021 - 05/2004
8	Estrogens (Estrogen)FDA Link 01/2020 - 06/2006
7	Messenger RNA (mRNA)IBA 09/2021 - 01/2010
6	Pharmaceutical PreparationsIBA 11/2020 - 01/2002
6	DNA (Deoxyribonucleic Acid)IBA 01/2020 - 09/2006
5	Carboplatin (JM8)FDA LinkGeneric 10/2022 - 01/2002
5	AnthracyclinesIBA 01/2022 - 12/2005
5	Platelet-Derived Growth Factor Receptors (Platelet-Derived Growth Factor Receptor)IBA 01/2021 - 07/2009
5	taxaneIBA 12/2019 - 12/2007
5	Sunitinib (Sutent)FDA Link 01/2016 - 08/2009
4	Doxorubicin (Adriamycin)FDA LinkGeneric 10/2022 - 06/2003
4	B7-H1 AntigenIBA 09/2021 - 01/2019
4	ParaffinIBA 10/2016 - 03/2004
4	human ERBB2 proteinIBA 06/2013 - 08/2011
3	Paclitaxel (Taxol)FDA LinkGeneric 10/2022 - 01/2002
3	Aromatase InhibitorsIBA 01/2022 - 10/2013
3	Cytochrome P-450 CYP2D6 (CYP2D6)IBA 12/2021 - 01/2018
3	LigandsIBA 09/2021 - 11/2008
3	ErbB Receptors (EGF Receptor)IBA 08/2021 - 01/2011
3	Platelet-Derived Growth Factor beta Receptor (Receptor, Platelet Derived Growth Factor beta)IBA 01/2021 - 07/2009
3	Granulocyte Colony-Stimulating Factor (G-CSF)IBA 01/2020 - 01/2007
3	Taxoids (Taxanes)IBA 12/2019 - 12/2005
3	Dexamethasone (Maxidex)FDA LinkGeneric 01/2019 - 11/2017
3	Estrogen Receptor alphaIBA 01/2019 - 07/2006
3	Platelet-Derived Growth FactorIBA 11/2018 - 07/2009
3	Vascular Endothelial Growth Factor A (Vascular Endothelial Growth Factor)IBA 11/2017 - 12/2003
3	Indicators and Reagents (Reagents)IBA 05/2011 - 09/2006
3	Methotrexate (Mexate)FDA LinkGeneric 03/2007 - 12/2005
3	Thiotepa (Triethylenethiophosphoramide)FDA LinkGeneric 06/2006 - 01/2002
2	pembrolizumabIBA 10/2022 - 01/2020
2	4- (4- dihexadecylaminostyryl)- N- methylpyridium (DiA)IBA 11/2021 - 04/2016
2	pertuzumabIBA 01/2021 - 07/2014
2	Everolimus FDA Link 01/2021 - 01/2011
2	Gonadotropin-Releasing Hormone (GnRH)FDA Link 01/2020 - 08/2011
2	Immune Checkpoint InhibitorsIBA 01/2020 - 01/2018
2	Cyclin D1IBA 01/2019 - 09/2012
2	Interleukin-6 (Interleukin 6)IBA 01/2019 - 10/2015
2	Lenalidomide (CC 5013)FDA Link 01/2019 - 11/2017
2	EnzymesIBA 11/2018 - 12/2003
2	PanobinostatIBA 07/2018 - 01/2018
2	Monoclonal AntibodiesIBA 01/2018 - 01/2007
2	Bevacizumab (Avastin)FDA Link 01/2018 - 01/2018
2	Sorafenib (BAY 43-9006)FDA Link 12/2017 - 11/2008
2	Capecitabine (Xeloda)FDA Link 12/2017 - 05/2007
2	Estradiol (Delestrogen)FDA LinkGeneric 10/2016 - 07/2006
2	Fulvestrant (Faslodex)FDA Link 06/2012 - 10/2010
2	Vinorelbine (Navelbine)FDA LinkGeneric 01/2011 - 01/2011
2	Complementary DNA (cDNA)IBA 05/2010 - 03/2004

Therapy/Procedure

61	Therapeutics 10/2022 - 01/2002
39	Drug Therapy (Chemotherapy) 10/2022 - 01/2002
19	Adjuvant Chemotherapy 07/2022 - 12/2005
18	Neoadjuvant Therapy 10/2022 - 01/2002
10	Radiotherapy 01/2022 - 01/2002
8	Immunotherapy 09/2021 - 01/2016
2	Segmental Mastectomy (Lumpectomy) 01/2021 - 01/2018
2	Combination Drug Therapy (Combination Chemotherapy) 04/2018 - 09/2014
2	Aftercare (After-Treatment) 11/2017 - 01/2016